RxDoctor Payments Data

Bhavank Doshi, MD

Internal Medicine · Pittsburgh, PANPI 1497713630

Payments from drug & device makers

$1,356in general payments, 2019–2025

Across 87 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$159
  • Amgen$128
  • GSK$114
  • Novo Nordisk$107
  • Boehringer Ingelheim$103
  • Novartis$102
  • plus $643 from 13 others

What the payments were for

  • Food & beverage$1,34199%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,356 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$101,826
Medicare patients
199
Services billed
1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban755$313,852
OzempicSemaglutide111$134,471
JardianceEmpagliflozin104$82,455
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$82,136
TradjentaLinagliptin106$66,535
IngrezzaValbenazine Tosylate16$65,693
XareltoRivaroxaban146$62,026
TrulicityDulaglutide72$48,162
JentaduetoLinagliptin/Metformin Hcl72$36,986
Breo ElliptaFluticasone/Vilanterol75$36,024
EntrestoSacubitril/Valsartan85$33,159
Combivent RespimatIpratropium/Albuterol Sulfate42$25,780
MyrbetriqMirabegron67$25,611
JanuviaSitagliptin Phosphate26$18,475
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$18,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat, Stiolto Respimat$103$226,082347 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$114$136,385225 claims
Novo NordiskOzempic$107$134,471111 claims
Johnson & JohnsonXarelto$60$62,026146 claims
Lilly USA, LLCTrulicity, Mounjaro$28$61,99185 claims
NovartisEntresto$102$33,15985 claims
AstraZenecaLokelma, Farxiga$42$26,36146 claims
Astellas Pharma US IncMyrbetriq$13$25,61167 claims
MerckJanuvia$102$18,47526 claims
AbbVieLinzess$50$12,60517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →